This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

AMPLIFY Clinical Trial

Choose ELIQUIS® for your patients with acute DVT / PE

In the AMPLIFY study, ELIQUIS demonstrated comparable efficacy and a significant reduction in the risk of major bleeding vs. enoxaparin / warfarin in patients receiving treatment for DVT / PE.1,2*

amplify result amplify result

Visit this page for more information on ELIQUIS dosing for DVT / PE.

ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.2

Footnotes:

  • *The AMPLIFY clinical trial was a randomised, double-blind, non-inferiority trial in 5,395 patients with acute VTE. Efficacy analyses were based on ITT population for whom the outcome status at 6 months was documented. All safety analyses included data obtained from patients during study treatment, defined as the time from administration of the first dose until 48 hours after the last dose was administered.1
  • †The primary efficacy endpoint was the incidence of the adjudicated composite of recurrent symptomatic venous thromboembolism VTE or death from any cause related to venous thromboembolism.1 Recurrent venous thromboembolism included fatal or non-fatal PE and DVT.1
  • ‡The primary safety endpoint was the incidence of an adjudicate of major bleeding.1 For patients who had more than one event, only the first was counted.1
  • §The secondary safety endpoint was the composite of major or CRNM bleeding events.1 For patients who had more than one event, only the first was counted.1
  • This link is to a third-party site unaffiliated with the Pfizer / BMS Alliance. Please abide by the terms of use of the site.
  • CI = Confidence Interval   CRNM = Clinically Relevant Non-Major Bleeding   DVT = Deep Vein Thrombosis   ITT= Intention-to-Treat N = Total number of patients in the ELIQUIS group or the enoxaparin / warfarin group   n = Number of patients with event   PE = Pulmonary Embolism   RR = Relative Risk   VTE = Venous Thromboembolism

References:

  1. Agnelli G et al. N Engl J Med 2013; 369: 799–808.
  2. ELIQUIS®(apixaban) Summary of Product Characteristics.

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com